Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Point-of-care testing for anticoagulation monitoring in neuroendovascular procedures.

Literature DB >> 21920856

Point-of-care testing for anticoagulation monitoring in neuroendovascular procedures.

H M Hussein¹, A L Georgiadis, A I Qureshi.

Abstract

POC testing is defined as diagnostic testing at or near the site of patient care. Rapid measurement of the intensity of anticoagulation and, more recently, platelet inhibition allows dose titration of adjuvant medications such a heparin and antiplatelet agents during neuroendovascular procedures. However, knowledge among practicing physicians regarding the pathophysiologic basis of these measurements and variations in knowledge about the differences among devices is often limited. This review discusses the role of anticoagulation in endovascular procedures and the currently available POC tests for anticoagulation monitoring.

Entities: Chemical Species

Mesh：

Substances：
Anticoagulants

Year: 2011 PMID： 21920856 PMCID： PMC7965513 DOI： 10.3174/ajnr.A2621

Source DB: PubMed Journal: AJNR Am J Neuroradiol ISSN： 0195-6108 Impact factor: 3.825

83 in total

Review 1. Stent-assisted endoluminal revascularization for the treatment of intracranial atherosclerotic disease.

Authors: Elad I Levy; Alan S Boulos; Lee R Guterman
Journal: Neurol Res Date: 2002-06 Impact factor: 2.448

2. Percutaneous transluminal coronary angioplasty: comparison of arterial vs. venous activated clotting time.

Authors: G R Pesola; A Johnson; D A Pesola
Journal: Cathet Cardiovasc Diagn Date: 1996-02

3. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time.

Authors: T Ammar; L E Scudder; B S Coller
Journal: Circulation Date: 1997-02-04 Impact factor: 29.690

4. GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood.

Authors: M I Furman; L A Krueger; A L Frelinger; M R Barnard; M A Mascelli; M T Nakada; A D Michelson
Journal: Thromb Haemost Date: 2000-09 Impact factor: 5.249

5. A novel point-of-care assay for the monitoring of low-molecular weight heparins in the cardiac catheterization laboratory.

Authors: Jonathan D Marmur; Manish Lakhani; Soumaya El Rouby; Erdal Cavusoglu
Journal: J Invasive Cardiol Date: 2008-09 Impact factor: 2.022

6. Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial.

Authors: Gilles Montalescot; Marc Cohen; Genevieve Salette; Walter J Desmet; Carlos Macaya; Philip E G Aylward; Ph Gabriel Steg; Harvey D White; Richard Gallo; Steven R Steinhubl
Journal: Eur Heart J Date: 2008-02 Impact factor: 29.983

7. Stenting of symptomatic M1 stenosis of middle cerebral artery: an initial experience of 40 patients.

Authors: Wei-Jian Jiang; Yong-Jun Wang; Bin Du; Su-Xiang Wang; Gui-Hong Wang; Min Jin; Jian-Ping Dai
Journal: Stroke Date: 2004-05-06 Impact factor: 7.914

8. Impact of final activated clotting time after transradial coronary stenting with maximal antiplatelet therapy.

Authors: Olivier F Bertrand; Josep Rodés-Cabau; Stéphane Rinfret; Eric Larose; Rodrigo Bagur; Guy Proulx; Onil Gleeton; Olivier Costerousse; Robert De Larochellière; Louis Roy
Journal: Am J Cardiol Date: 2009-11-01 Impact factor: 2.778

Review 9. Bivalirudin.

Authors: Theodore E Warkentin; Andreas Greinacher; Andreas Koster
Journal: Thromb Haemost Date: 2008-05 Impact factor: 5.249

6. Comparison of activated clotting times measured using the Hemochron Jr. Signature and Medtronic ACT Plus during cardiopulmonary bypass with acute normovolemic haemodilution.

Authors: Jung Min Lee; Eun Young Park; Kyung Mi Kim; Jong Chan Won; Tack Koon Jung; Soo Kyung Lee
Journal: J Int Med Res Date: 2017-10-04 Impact factor: 1.671

6 in total

Point-of-care testing for anticoagulation monitoring in neuroendovascular procedures.

Review 1. Stent-assisted endoluminal revascularization for the treatment of intracranial atherosclerotic disease.

2. Percutaneous transluminal coronary angioplasty: comparison of arterial vs. venous activated clotting time.

3. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time.

4. GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood.

5. A novel point-of-care assay for the monitoring of low-molecular weight heparins in the cardiac catheterization laboratory.

6. Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial.

7. Stenting of symptomatic M1 stenosis of middle cerebral artery: an initial experience of 40 patients.

8. Impact of final activated clotting time after transradial coronary stenting with maximal antiplatelet therapy.

Review 9. Bivalirudin.

10. Point-of-Care Testing of Hemostasis in Cardiac Surgery.

Review 1. Off-label use of drugs and devices in the neuroendovascular suite.

2. Monitoring of the heparinization in the rabbit animal model during endovascular interventions.

Review 3. Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays.

Review 4. Management of non-vitamin K antagonist oral anticoagulants in the perioperative setting.

Review 5. Technology Advancements in Blood Coagulation Measurements for Point-of-Care Diagnostic Testing.

6. Comparison of activated clotting times measured using the Hemochron Jr. Signature and Medtronic ACT Plus during cardiopulmonary bypass with acute normovolemic haemodilution.